Login
Request Demo
Publications

Real-World Study: Treatment Persistence in Pulmonary Arterial Hypertension Patients

The study analysed real-world data to compare treatment persistence and adherence among PAH patients on ERAs in Japan. Results showed significantly higher persistence with a medication compared to the other two medications.

Authors: Junichi Omura, Yogeshwar Makanji, Nobuhiro Tanabe, Dae Young Yu, Jin Yu Tan, Sooyeol Lim, Mahsa H. Kouhkamari, Jeremy Casorso, David Bin-Chia Wu, Paul Bloomfield

Pulmonary Therapy https://doi.org/10.1007/s41030-023-00244-w | Date: November 22, 2023

Download document

Download Now
comparative effectivenessERAshypertensionPAHreal world evidence

Related Resources

Real-world study of the use of azacitidine in myelodysplasia in Australia

Uncovering real-world insights into MDS treatment in Australia: Our study in eJHaem highlights the importance of treatment adherence and the need for innovative solutions.

Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia

This study aimed to examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.

Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions

Gout is the most common form of inflammatory arthritis in men. Despite the availability of effective urate-lowering therapies (ULT), the management of gout is suboptimal due to poor persistence with ULT. This study examined national prescribing patterns of ULT to...

Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general...